Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.

Abstract

This study compares the efficacy and safety of lenvatinib and programmed cell death protein (PD)-1 versus lenvatinib alone for advanced hepatocellular carcinoma (Ad-HCC) refractory to hepatic arterial infusion chemotherapy (HAIC). From April 2016 to September 2021, 145 patients with Ad-HCC refractory to HAIC based on modified Response Evaluation Criteria in Solid Tumors criteria were enrolled by two radiologists and classified into the HAIC-lenvatinib group (H-L, n=87) and HAIC-lenvatinib-PD-1 group (H-L-P, n=58). A propensity score-matching method was used to reduce selective bias. The overall survival (OS) and postprogression-free survival (PPS) rates were compared using the Kaplan-Meier method with log-rank test. Multivariable analyses of independent prognostic factors were evaluated by means of the forward stepwise Cox regression model. After propensity score matching 1:1, the median OS was 43.6months in the H-L-P group and was significantly longer than that (18.9months) of the H-L group (p=.009). The median PPS was 35.6months in the H-L-P group and was significantly longer than that (9.4months) of the H-L group (p=.009). Multivariate analyses showed that the factors that ‎significantly affected the OS were‎ α-fetoprotein (hazard ratio [HR], 2.14; 95% CI, 1.26-3.98; p=.006), early response to HAIC (HR, 0.44; 95% CI, 1.20-3.85; p=.009), and H-L treatment (HR, ‎0.52; 95% CI, 0.30-0.86; p=.012). Modified albumin-bilirubin grade (HR, 1.32; 95% CI, 1.03-1.70; p=.026), early response to HAIC (HR, 0.44; 95% CI, 0.25-0.77; p=.004), and H-L (HR, ‎0.47‎; 95% CI, 0.28-0.78; p=.003) significantly affected the PPS. This combination therapy of PD-1 inhibitors plus lenvatinib has promising survival benefits in the management of patients with Ad-HCC refractory to HAIC. Lenvatinib plus programmed death 1 inhibitor is an effective and safe postprogression treatment and improved significantly overall survival and postprogression-free survival compared with lenvatinib alone in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.